Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study
Approaches to risk assessment in pulmonary arterial hypertension (PAH) include the noninvasive French risk assessment approach (number of low-risk criteria based on the European Society of Cardiology and European Respiratory Society guidelines) and Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) 2.0 risk calculator. The prognostic and predictive value of these methods for morbidity/mortality was evaluated in the predominantly prevalent population of GRIPHON, the largest randomized controlled trial in PAH.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Olivier Sitbon, Kelly M. Chin, Richard N. Channick, Raymond L. Benza, Lilla Di Scala, Sean Gaine, Hossein-Ardeschir Ghofrani, Irene M. Lang, Vallerie V. McLaughlin, Ralph Preiss, Lewis J. Rubin, G érald Simonneau, Victor F. Tapson, Nazzareno Galiè, Mari Tags: ORIGINAL CLINICAL SCIENCE Source Type: research
More News: Cardiology | France Health | Heart | Heart Transplant | Hypertension | Lung Transplant | Respiratory Medicine | Science | Study | Transplant Surgery | Transplants